Abstract 5455
Background
Acid-inhibitory drugs (e.g. proton pump inhibitors - PPIs) increase intragastric pH, which may decrease solubility, bioavailability, and efficacy of oral cancer drugs. Furthermore, polypharmacy in cancer patients is common and different requirements for treatment with or without food can impact compliance. Tepotinib is an oral, highly selective MET inhibitor being investigated in patients with solid tumors with MET dysregulation (METex14 mutations or MET amplification). In the pivotal clinical trial, tepotinib has been administered with breakfast; this represents the intended posology. Tepotinib has pH-dependent low solubility, suggesting that food intake and/or co-administration with a PPI may impact bioavailability. We investigated the effects of the PPI omeprazole and food on tepotinib.
Methods
In a 3-period, cross-over study, healthy volunteers (n = 12) received 500 mg/day tepotinib as a single dose 30 mins after a continental breakfast (treatment A) and co-administered on Day 5 after receiving omeprazole (40 mg QD for 5 days) under fasted conditions (treatment B) and after a continental breakfast (treatment C). The impact of omeprazole on the AUC0-t, AUC0-∞, and Cmax of tepotinib under fed conditions was evaluated comparing treatments A and C; corresponding ratios of the geometric least-squares means (GLSM) (90% CI) were reported. In a separate study, food effect was investigated in healthy volunteers (n = 12) by administering single doses of 500 mg tepotinib under fasted state and after a high-fat, high-calorie breakfast.
Results
In the first study, there was a negligible effect of omeprazole co-administration on the bioavailability of tepotinib under fed conditions. The GLSM ratios (90% CI) for treatment C/A were 1.09 (1.01, 1.17) for AUC0-t; 1.10 (1.02, 1.19) for AUC0-∞; and 1.04 (0.93, 1.17) for Cmax. In the second study, the ratio (90% CI) of “high-fat” /”fasted” for tepotinib AUC0-∞ was 1.87 (1.64, 2.13) and for Cmax was 2.37 (2.16, 2.59).
Conclusions
The intended posology of tepotinib, i.e. with food, is in agreement with the moderate food effect (approximately 2-fold increase in exposure of tepotinib). When tepotinib is administered at 500 mg/day together with food, co-administration of PPI is not expected to have clinically relevant drug interactions.
Clinical trial identification
NCT03531762 and NCT03629223.
Editorial acknowledgement
Medical writing assistance (funded by Merck KGaA, Darmstadt, Germany) was provided by Sandra Cuscó, PhD of Bioscript Group (Macclesfield, UK).
Legal entity responsible for the study
Merck Healthcare KGaA.
Funding
Merck Healthcare KGaA.
Disclosure
R. Strotmann: Full / Part-time employment: Merck Healthcare KGaA. A. Becker: Full / Part-time employment: Merck Healthcare KGaA. A. Krebs-Brown: Full / Part-time employment: Merck Healthcare KGaA. N. Mammasse: Full / Part-time employment: Merck Healthcare KGaA. Ö. Yalkinoglu: Full / Part-time employment: Merck Healthcare KGaA. All other authors have declared no conflicts of interest.
Resources from the same session
3158 - Tobacco Retail Access and Tobacco Cessation Among Head and Neck Cancer (HNC) Survivors
Presenter: Lawson Eng
Session: Poster Display session 1
Resources:
Abstract
5511 - ASSERT: A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Patients Treated for Moderate to Severe Hyponatremia Secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion (SIADH) in Italy (Lung Cancer Cohort)
Presenter: Rossana Berardi
Session: Poster Display session 1
Resources:
Abstract
3821 - Efficacy and safety of controlled ovarian stimulation with or without letrozole co-administration for fertility preservation: A systematic review and meta-analysis.
Presenter: Benedetta Bonardi
Session: Poster Display session 1
Resources:
Abstract
2168 - Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy
Presenter: Tineke Vandenbroucke
Session: Poster Display session 1
Resources:
Abstract
5855 - Update of the registry of young women with cancer by the International Network of Cancer, Infertility and Pregnancy
Presenter: Charlotte Maggen
Session: Poster Display session 1
Resources:
Abstract
5156 - Erectile dysfunction in patients with metastatic renal cell carcinoma
Presenter: Ilya Tsimafeyeu
Session: Poster Display session 1
Resources:
Abstract
4992 - Exercise level, interest and preferences in cancer patients.
Presenter: Alice Avancini
Session: Poster Display session 1
Resources:
Abstract
3427 - Filling the Gaps in Informed Consent for Advanced Cancer Patients considering Phase 1 Oncology Trials - an in-depth Qualitative Study of Key Stakeholders at a large United Kingdom Phase 1 unit
Presenter: Abhijit Pal
Session: Poster Display session 1
Resources:
Abstract
3537 - Breast Cancer Patients’ Quality of Life: Real World Data
Presenter: Thanos Kosmidis
Session: Poster Display session 1
Resources:
Abstract
4761 - High-sensitivity troponin as a cardiotoxicity biomarker in breast cancer treatment
Presenter: Joana Simões
Session: Poster Display session 1
Resources:
Abstract